Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

320
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
320
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.8K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.8K
Pharmacokinetic–Pharmacodynamic Relationship: Model Components01:14

Pharmacokinetic–Pharmacodynamic Relationship: Model Components

189
Pharmacokinetic-pharmacodynamic (PK–PD) modeling is essential in drug development and clinical pharmacology. It provides a quantitative framework to predict drug behavior and response over time. This approach integrates pharmacokinetics (PK), which describes the drug's absorption, distribution, metabolism, and excretion, with pharmacodynamics (PD), which characterizes the drug’s biological effects and mechanisms of action.The disposition kinetics of a drug determine its plasma...
189
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

132
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
132
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

87
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
87
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

957
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
957

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Simulating Cancer Recurrence Patterns From Post-Treatment Viable Tumor Burden Distributions.

JCO clinical cancer informatics·2026
Same author

Measurable imaging-based changes in enhancement of intrahepatic cholangiocarcinoma after radiotherapy reflect physical mechanisms of response.

NPJ systems biology and applications·2025
Same author

Human nerve growth factor delivery to the retina: Quantitative methodology and mathematical modeling in preclinical settings.

PNAS nexus·2025
Same author

Rational Design of Safer Inorganic Nanoparticles via Mechanistic Modeling-Informed Machine Learning.

ACS nano·2025
Same author

Author Correction: Insights from a multiscale framework on metabolic rate variation driving glioblastoma multiforme growth and invasion.

Communications engineering·2025
Same author

Development of a Multiscale Mechanistic Model for Predicting Tumor Response to Anti-miR-155.

Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference·2025

Related Experiment Video

Updated: Apr 18, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K

Integrated PK-PD and agent-based modeling in oncology.

Zhihui Wang1, Joseph D Butner, Vittorio Cristini

  • 1Department of Pathology, University of New Mexico, Albuquerque, NM, 87131, USA.

Journal of Pharmacokinetics and Pharmacodynamics
|January 16, 2015
PubMed
Summary

Mathematical modeling, combining pharmacokinetic-pharmacodynamic (PK-PD) and agent-based modeling (ABM), offers new insights into cancer drug dynamics and tumor growth. This integrated approach generates testable hypotheses for optimizing cancer therapies.

More Related Videos

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

2.2K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.8K

Related Experiment Videos

Last Updated: Apr 18, 2026

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.2K
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
09:13

Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis

Published on: January 5, 2024

2.2K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

5.8K

Area of Science:

  • Computational biology
  • Mathematical oncology
  • Translational medicine

Background:

  • Mathematical modeling complements traditional biomedical research for predicting outcomes and optimizing therapies.
  • Pharmacokinetic-pharmacodynamic (PK-PD) and agent-based modeling (ABM) are established methods in cancer research.
  • Combining PK-PD and ABM approaches offers deeper insights into drug dynamics and tumor growth.

Purpose of the Study:

  • To review recent studies integrating PK-PD and ABM for cancer research.
  • To highlight how combined modeling generates experimentally testable hypotheses.
  • To discuss future directions for integrated modeling in oncology.

Main Methods:

  • Review of recent literature on combined PK-PD and ABM studies in cancer.
  • Analysis of studies focusing on drug dynamics and tumor growth prediction.
  • Identification of experimentally validated hypotheses derived from integrated models.

Main Results:

  • Combined PK-PD and ABM approaches provide a more comprehensive understanding of cancer drug effects.
  • Integration facilitates the generation of novel, testable hypotheses for therapeutic strategies.
  • Recent studies demonstrate the utility of this combined approach in predicting tumor response.

Conclusions:

  • The integration of PK-PD and ABM is a powerful strategy for advancing cancer research.
  • This combined modeling approach enhances the prediction of treatment efficacy and tumor progression.
  • Future research should further explore and validate combined modeling for personalized cancer therapy.